Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus

Journal of Infectious Diseases

Volumn 186, Issue 10, 2002, Pages 1508-1513

  Van Rompay, Koen K A ^a   Schmidt, Kimberli A ^a   Lawson, Jonathan R ^a   Singh, Raman ^a   Bischofberger, Norbert ^b   Marthas, Marta L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR DISOPROXIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST FEEDING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS INFECTION; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; MACACA; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0037111084     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344360     Document Type: Article

References (19)

1. De Cock K, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. JAMA 2000;283:1175-82.
2. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1. JAMA 2000;283:1167-74.
3. Balzarini J, Naesens L, Verbeken E, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998;12:1129-38.
4. Tsai CC, Follis KE, Beck TW, et al. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA). Science 1995;270:1197-9.
5. Robbins BL, Srinivas RV, Kim C, Bischofberger N. Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonometh-oxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA.Antimicrob Agents Chemother 1998;42:612-7.
6. Van Rompay KKA, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 1998;12:F79-83.
7. Van Rompay KKA, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N. Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184:429-38.
8. Lohman BL, Higgins J, Marthas ML, Marx PA, Pedersen NC. Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol 1991;29:2187-92.
9. Booth J, Sawyer L, McNelley E, et al. Performance characteristics of a highly sensitive quantitative assay for SIV RNA using branched DNA technology [abstract 129]. In: Programs and abstracts of the 18th annual symposium on Nonhuman Primate Models for AIDS (Madison, Wisconsin). J Medical Primatol 2001::242.
10. Lewis P, Nduati R, Kreiss JK, et al. Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis 1998;177:34-9.
11. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999;180:93-8.
12. Barditch-Crovo P, Decks SG. Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
13. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retro-virus (human immunodeficiency virus type 2). J Virol 2000;74:9771-5.
14. Böttiger D, Vrang L, Öberg B. Influence of the infectious dose of simian immunodeficiency virus on the acute infection in cynomolgus monkeys and on the effect of treatment with 3′-fluorothymidine. Antivir Chem Chemother 1992;3:267-71.
15. Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate: Functional and morphological studies. J Exp Med 1987;166:1654-67.
16. Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000;436:560-6.
17. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999;285:1261-5.
18. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainbert MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997;71:3023-30.
19. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74:6087-95.